<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002611</url>
  </required_header>
  <id_info>
    <org_study_id>19DDI13016</org_study_id>
    <nct_id>NCT02002611</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study(Lobeglitazone, Warfarin)</brief_title>
  <official_title>Open Label, Randomized, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Lobeglitazone and Warfarin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a pharmacokinetic drug interaction between
      lobeglitazone and warfarin in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From day 1 to day 12, lobeglitazone 0.5mg is administered daily to Group 1 subjects during
      period 1. Then on day 5,warfarin 25mg is co-administered Group 1 subjects at period 1. After
      10 day-break, warfarin 25mg is administered Group 1 subjects at period 2. On period 2,
      lobeglitazone is not administered.

      Group 2 is administered in reverse order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess AUC of lobeglitazone</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Cmax of lobeglitazone</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess AUC of S-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Cmax of S-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess AUC of R-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Cmax of R-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess tmax of lobeglitazone</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess t1/2 of lobeglitazone</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess CL/F of lobeglitazone</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Vd/F of lobeglitazone</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess tmax of S-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess t1/2 of S-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess CL/F of S-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Vd/F of S-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess tmax of R-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess t1/2 of R-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess CL/F of R-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Vd/F of R-warfarin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Lobeglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Warfarin 25 mg once at period 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobeglitazone</intervention_name>
    <arm_group_label>Lobeglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy male volunteer between 19 and 55 years old.

          -  BMI between 19 and 27.

          -  Signed the informed consent form prior to study participation.

          -  Able to participate in the entire trial

        Exclusion Criteria:

          -  Clinically significant hepatic, renal, digestive system, respiratory system, endocrine
             system, nervous system, hematologic, cardiovascular system, tumor or have history of
             tumor

          -  Clinically significant hemorrhagic disease

          -  Genetic problems such as galactose intolerance, Lapp lactase deficiency,
             glucose-galactose malabsorption

          -  Have hypersensitivity reactions history for lobeglitazone, warfarin, excipient of IP
             or aspirin, antibiotics

          -  Medication which might significantly alter the absorption, distribution, metabolism,
             or excretion of investigational products within 30 days prior to screening

          -  Participated in the other clinical trials and administrated IP within 60 days prior to
             screening

          -  Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days before
             screening

          -  Previously donate whole blood within 60 days or component blood within 30 days

          -  sit SBP &lt; 90mmHg or sit SBP ≥ 140mmHg or sit DBP &lt; 60mmHg or sit DBP ≥ 90mmHg

          -  A heavy alcohol consumer (alcohol &gt; 140 g/week) or cannot stop drinking

          -  A heavy smoker (cigarette &gt; 10 cigarettes per day) or cannot stop smoking

          -  A heavy caffeine consumer (more than 4cups per a day) or A heavy grapefruit consumer
             (more than 1cup per a day) or cannot stop having

          -  Positive for the Triage TOX drug on urine

          -  Positive for HIV antibody, HBsAg, HCV antibody test

          -  AST, ALT or Total bilirubin &gt; UNL * 1.5

          -  Estimated GFR &lt; normal limit

          -  INR, aPTT over the normal limit

          -  Clinically significant laboratory test result

          -  Clinically significant ECG

          -  An impossible one who participates in clinical trial by investigator's decision
             including other reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Wook Ko, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lobeglitazone</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Drug-Drug interaction</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

